Adds 258,000 sq.-ft. to current Cookeville footprint and represents expansion into biologics, cold chain storage and third-party logistics distribution.
Cell & gene therapy companies have faced unique challenges due to the nature of their therapies, this is especially true for autologous cell therapies.
Mark Stielow, Senior Director of Cell Manufacturing & Technical Operations, Adaptimmune06.10.20
Opportunities across next-gen products, transforming how chronic diseases are treated, and favorable government regulations are driving today's market.
Thomas N. Podesta, Global Vice President, Sales, West Contract Manufacturing06.02.20
Dr. Ural of Ernst & Young LLP discusses market dynamics, enduring therapeutic areas, near term M&A, and how industry can use this time for transformation